Company intelligence / Profile preview

Sunflower Therapeutics

Medford, Massachusetts, United Statessunflowertx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sunflower Therapeutics has launched its Daisy Petal™ and Dahlia Petal™ continuous perfusion fermentation systems. These enable five-to-ten times higher space-time yields than traditional fed-batch methods for diverse protein production. The company’s solutions are being adopted by educational foundations and biomanufacturers globally. No direct clinical results as the company is an enabling technology/platform provider.

Therapeutic areas: Other
Modalities: ProteinRecombinant proteinBiologic
Industry: Non-Drug Biotech

Partnerships

Optimal Biotech Group (exclusive sales representation in US West Coast/Canada)PharmNXT Biotech LLP (distribution partner in Asia)BioBuilder Education Foundation (first system installation/delivery)

Beyond the preview

Go deeper on Sunflower Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunflower Therapeutics.

Explore the full profile